Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Summary as of Jun 27, 2018

June 27, 2018 - By Sarah Harris

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage

In total 4 analysts cover Celldex Therapeutics (NASDAQ:CLDX). “Buy” rating has 0, “Sell” are 0, while 4 are “Hold”. (NASDAQ:CLDX) has 0 bullish analysts. 4 are the (NASDAQ:CLDX)’s ratings reports on Jun 27, 2018 according to StockzIntelligence Inc. On Thursday, March 8 Leerink Swann maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) rating. Leerink Swann has “Market Perform” rating and $3 target. On Tuesday, April 17 Cantor Fitzgerald maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) with “Neutral” rating. In Thursday, March 8 report Jefferies maintained the stock with “Hold” rating. The stock rating was downgraded by Cowen & Co to “Hold” on Monday, April 16. Listed here are Celldex Therapeutics, Inc. (NASDAQ:CLDX) PTs and latest ratings.

17/04/2018 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Neutral Old Target: $9 New Target: $3 Maintain
16/04/2018 Broker: Cowen & Co Rating: Hold Downgrade
08/03/2018 Broker: Jefferies Rating: Hold New Target: $3.0 Maintain
08/03/2018 Broker: Leerink Swann Old Rating: Market Perform New Rating: Market Perform Old Target: $4 New Target: $3 Maintain

The stock decreased 2.14% or $0.011 during the last trading session, touching $0.5029.Celldex Therapeutics, Inc. has 5.16 million shares volume, 33.71% up from normal. CLDX is downtrending and has moved 79.56% since June 27, 2017. CLDX underperformed by 92.13% the S&P 500.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics.The company has $72.11 million market cap. The Company’s drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer.Last it reported negative earnings. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers.

There’s a substantial Celldex Therapeutics, Inc. (NASDAQ:CLDX) news released by Seekingalpha.com. It’s an article titled: “Celldex Therapeutics Salvage Value” on June 15, 2018.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.